Evaluation of the effect of cognitive bahavioral therapy on fibromyalgia patients

Evaluation of the effect of cognitive-behavioral therapy on the serum TNF-a, IL-8, IL-6, total oxidant status, and total antioxidant capacity of fibromyalgia patients in comparison with Duloxetine treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016120530871N3

Enrollment

Registered

2016-12-18

Start date

2017-01-20

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia. Fibromyalgia

Interventions

Intervention 1: Intervention group 1: Cognitive behavioral therapy in 20 sessions. Intervention 2: Intervention group 2: (Medication, 60 mg/day, 5 months). Intervention 3: Control group: No treatment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The diagnosis of fibromyalgia according to the criteria of American college of Rheumatology (2010) Exclusion criteria:

Exclusion criteria

Exclusion criteria: Vitamin D deficiency. Patients with the history of fibromyalgia treatment. Metabolic disease; Diabetes Mellitus; mental illnesses; Other rheumatologic disorders; hepatic diseases; chronic renal disorders; heart diseases; Malnutrition; and cancer.

Design outcomes

Primary

Measure	Time frame
IL-8. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;Serum total oxidant status. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: Colorimetric assay.;Serum total antioxidant capacity. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: Colorimetric assay.	—

Measure

Time frame

IL-8. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;TNF-a. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;IL-6. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: ELISA.;Serum total oxidant status. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: Colorimetric assay.;Serum total antioxidant capacity. Timepoint: Before the start of the intervention and after the end of the intervention. Method of measurement: Colorimetric assay.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Mirzaei

Iran University of Medical Sciences

mirzaeialireza26@gmail.com+98 21 3354 2041

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026